Status:
TERMINATED
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
New York Presbyterian Hospital
Weill Medical College of Cornell University
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better. In this study, the patient will get either the...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Patients must have pathologically confirmed non-muscle invasive urothelial bladder carcinoma by the Department of Pathology New York Presbyterian Hospital, Weill Medical College of Cornell University or Memorial Sloan Kettering Cancer Center or a documented past history of Ta or T1 non-muscle invasive urothelial bladder tumors.
- Intermediate Risk UBC patients: Recurrence Total Score = 1 to 9
Exclusion
- Any intravesical therapy within the past six months prior to current diagnosis
- Currently being treated or scheduled to have radiation treatment for bladder cancer during the study
- Scheduled to have surgery for bladder cancer during the study
- Currently being treated or scheduled to have treatment with any chemotherapeutic agent during the study
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00974818
Start Date
September 1 2009
End Date
March 1 2012
Last Update
November 20 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Medical College of Cornell University
New York, New York, United States, 10021
2
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065